Evidence map›Paper›PMID 36690987›Full record

ArticleBMC pulmonary medicine2023

FAM83B promotes the invasion of primary lung adenocarcinoma via PI3K/AKT/NF-κB pathway.

Jing Zhang, Jiajia Wang, Ke Yue, Panpan Li, Wenping Shen, Xiaowen Qiao, Yan Wang, Xiaojuan Wu

Open access · goldAbstract read
In one paragraph

Article in BMC pulmonary medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. FAM83B regulates mitochondrial metabolism and anti-apoptotic activity in pulmonary adenocarcinoma.Apoptosis : an international journal on programmed cell death · 2024
    Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jing Zhang *Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, 250012, Shandong, China.
Jiajia Wang *Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, 250012, Shandong, China.
Ke YueDepartment of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, 250012, Shandong, China.
Panpan LiDepartment of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, 250012, Shandong, China.
Wenping ShenDepartment of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, 250012, Shandong, China.
Xiaowen QiaoDepartment of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, 250012, Shandong, China.
Yan WangDepartment of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, 250012, Shandong, China.
Xiaojuan WuDepartment of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, 250012, Shandong, China. xiaojuanwu0709@126.com.
Qilu Hospital of Shandong University · CNShandong University · CN

Funding

National Natural Science Foundation of China 81402181National Natural Science Foundation of Shandong Province ZR2019MH069
6 · The paper itself

Abstract

objectsThe family with sequence similarity 83B (FAM83B) is one of the markers for poor prognosis in several carcinomas, but the expression and the mechanism resulted in malignant phenotype in lung adenocarcinoma (LUAD) remain to be elucidated.

methodsData of RNA-seq in LUAD were downloaded from the cancer genome atlas (TCGA) database for differential expression and survival analysis, and immunohistochemistry was employed to analyze the protein expression of FAM83B in 126 cases of primary LUAD. The LUAD cell lines were collected for the detection of the effects on migration and invasion. Then, western blot was performed to measure the expression of tissue inhibitor of metalloproteinase (TIMP)-1 and activation of PI3K/AKT/NF-κB pathway.

resultsFAM83B was overexpressed in multiple types of carcinomas; The differential expression analysis revealed that the level of FAM83B was higher in LUAD than that in para-carcinoma; The patients with overexpression of FAM83B were with shorter overall survival (OS), disease specific survival (DSS) and progress free interval (PFI); Enrichment analysis suggested it was related to the focal adhesion of LUAD. Immunohistochemistry analysis demonstrated that higher FAM83B expression was positively related to lymph node metastasis in primary. Scratch assay and Borden chamber assay showed that the overexpression of FAM83B promoted migration and invasion activity in vitro. Furthermore, high level of FAM83B accelerated the tumorigenesis in vivo. Western blot showed that TIMP-1 was upregulated in H1299/FAM83B OE cells accompanying by the activation of PI3K/AKT/NF-κB pathway.

conclusionsFAM83B was a marker for poor prognosis of LUAD and it might promote the expression of TIMP-1 by activating PI3K/AKT/NF-κB pathway and then affect the ECM balance, which resulted in the migration and invasion of LUAD.

Indexed as

Adenocarcinoma of LungLung NeoplasmsCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansNeoplasm ProteinsNF-kappa BPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTissue Inhibitor of Metalloproteinase-1FAM83B protein, humanNeoplasm ProteinsNF-kappa BPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTissue Inhibitor of Metalloproteinase-1FAM83BInvasionLung adenocarcinomaMigrationTIMP-1

Identifiers

PMID36690987
PMCPMC9872310
OpenAlexW4317751998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.